Pharmaceutical

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE...

Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies

Press release Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of...

Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”...

error: Content is protected !!